Renaissance Technologies’s Acceleron Pharma XLRN Stock Holding History

Renaissance Technologies’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-37,200	Closed	-$4.76M	–	3872
2020 Q4	$4.76M	Sell	37,200 -168,007	-82%	-$19.7M	0.01%	1622
2020 Q3	$23.1M	Buy	205,207 +69,607	+51%	+$6.93M	0.02%	672
2020 Q2	$12.9M	Sell	135,600 -64,000	-32%	-$6.17M	0.01%	1074
2020 Q1	$17.9M	Buy	+199,600	New	+$15.5M	0.02%	836
2016 Q4	–	Sell	-57,600	Closed	-$2.08M	–	3556
2016 Q3	$2.08M	Buy	+57,600	New	+$1.91M	﹤0.01%	2162
2015 Q3	–	Sell	-64,300	Closed	-$2.03M	–	3448
2015 Q2	$2.03M	Buy	+64,300	New	+$2.08M	﹤0.01%	2050

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies's XLRN Position: Q1 2021 in Review

Renaissance Technologies sold out of Acceleron Pharma (XLRN) in Q1 2021, closing a stake of 37,200 shares — an estimated $4.76M sold.

Renaissance Technologies first reported a position in XLRN in Q2 2015 and held it in 6 quarters. The position peaked at $23.1M in Q3 2020. 256 funds tracked by Wall St. Rank hold XLRN as of Q1 2021.

Renaissance Technologies reported no remaining Acceleron Pharma position as of Q1 2021 after selling out during the quarter.
Renaissance Technologies sold 37,200 Acceleron Pharma shares in Q1 2021, an estimated $4.76M.
Renaissance Technologies first reported a position in Acceleron Pharma in Q2 2015 and held it in 6 quarters.
Renaissance Technologies's Acceleron Pharma position peaked at $23.1M in Q3 2020.
256 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2021.

Based on Renaissance Technologies's 13F filing for Q1 2021, filed 13 May 2021.